Alliance Pharma PLC (STU:DVL)
€ 0.52 0.005 (0.97%) Market Cap: 296.49 Mil Enterprise Value: 400.78 Mil PE Ratio: 0 PB Ratio: 1.12 GF Score: 75/100

Half Year 2024 Alliance Pharma PLC Earnings Call Transcript

Sep 30, 2024 / 09:00AM GMT
Release Date Price: €0.494 (+3.35%)
Nick Sedgwick;Andrew Franklin
Alliance Pharma PLC - Chief Executive Officer, Executive Director;Alliance

So good morning, everyone, and a very warm welcome to our interim results. It's my first presentation since joining as CEO on May 13. I'm delighted to have joined Alliance at such an important and exciting time for the company, having spent 30 years predominantly in the consumer health industry with a number of European, US, and global roles at large multinationals such as Reckitt and Coty.

Andrew will walk through the highlights of the first half and cover our H1 financial results in more detail. Only three months have passed since we presented our results for full year '23, and whilst little has changed financially, since then, we've begun to implement the changes to our operating model, our organizational structure, and recruited some great talent, which I'll cover later.

I will take you through each of the key brands before finishing with my observations from my first 100 days at Alliance, and after that, we'll move to Q&A. So over to Andrew.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot